NAT2 Polymorphism and Gastric Cancer Susceptibility: A Meta-analysis

Archives of Medical Research

Volumn 41, Issue 4, 2010, Pages 275-280

  Zhong, Xu ^a   Hui, Cao ^b   Xiao Ling, Wu ^a   Yan, Li ^a   Na, Luo ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Genetic susceptibility; Meta analysis; NAT2; Polymorphism; Stomach neoplasms

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; NAT2 PROTEIN, HUMAN;

ACETYLATION; ACETYLATOR PHENOTYPE; ARTICLE; BIOMEDICINE; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; DATA BASE; DISEASE CLASSIFICATION; EMBASE; GENOTYPE; HUMAN; META ANALYSIS; PHENOTYPE; QUANTITATIVE ANALYSIS; RACE; STOMACH CANCER; SYSTEMATIC REVIEW; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; STOMACH TUMOR;

ARYLAMINE N-ACETYLTRANSFERASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS;

EID: 77954637277     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.06.001     Document Type: Article

References (46)

1. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
2. Correa P., Haenszel W., Cuello C., et al. A model for gastric cancer epidemiology. Lancet 1975, 2:58-60.
3. Yokozaki H., Yasui W., Tahara E. Genetic and epigenetic changes in stomach cancer. Int Rev Cytol 2001, 204:49-95.
4. Gonzalez C.A., Sala N., Capella G. Genetic susceptibility and gastric cancer risk. Int J Cancer 2002, 100:249-260.
5. Kelley J.R., Duggan J.M. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003, 56:1-9.
6. Gao L., Nieters A., Brenner H. Meta-analysis: tumour invasion-related genetic polymorphisms and gastric cancer susceptibility. Aliment Pharmacol Ther 2008, 28:565-573.
7. Loh M., Koh K.X., Yeo B.H., et al. Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer 2009, 45:2562-2568.
8. Blum M., Grant D.M., McBride W., et al. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990, 9:193-203.
9. Hickman D., Pope J., Patil S.D., et al. Expression of arylamine N-acetyltransferase in human intestine. Gut 1998, 42:402-409.
10. Hein D.W., Doll M.A., Gray K., et al. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus. Cancer Res 1993, 53:509-514.
11. De Stefani E., Boffetta P., Mendilaharsu M., et al. Dietary nitrosamines, heterocyclic amines, and risk of gastric cancer: a case-control study in Uruguay. Nutr Cancer 1998, 30:158-162.
12. Hein D.W., Rustan T.D., Ferguson R.J., et al. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch Toxicol 1994, 68:129-133.
13. Hein D.W., Doll M.A., Fretland A.J., et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000, 9:29-42.
14. Zang Y., Doll M.A., Zhao S., et al. Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis 2007, 28:1665-1671.
15. Garcia-Closas M., Malats N., Silverman D., et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005, 366:649-659.
16. Marcus P.M., Hayes R.B., Vineis P., et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 2000, 9:461-467.
17. Brockton N., Little J., Sharp L., et al. N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 2000, 151:846-861.
18. Chen K., Jiang Q.T., He H.Q. Relationship between metabolic enzyme polymorphism and colorectal cancer. World J Gastroenterol 2005, 11:331-335.
19. Ochs-Balcom H.M., Wiesner G., Elston R.C. A meta-analysis of the association of N-acetyltransferase 2 gene (NAT2) variants with breast cancer. Am J Epidemiol 2007, 166:246-254.
20. Ambrosone C.B., Kropp S., Yang J., et al. Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis. Cancer Epidemiol Biomarkers Prev 2008, 17:15-26.
21. Agundez J.A. Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab 2008, 9:520-531.
22. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration; 2009.
23. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
24. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
25. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
26. Katoh T., Boissy R., Nagata N., et al. Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. Int J Cancer 2000, 85:46-49.
27. Boissy R.J., Watson M.A., Umbach D.M., et al. A pilot study investigating the role of NAT1 and NAT2 polymorphisms in gastric adenocarcinoma. Int J Cancer 2000, 87:507-511.
28. Ladero J.M., Agundez J.A., Olivera M., et al. N-acetyltransferase 2 single-nucleotide polymorphisms and risk of gastric carcinoma. Eur J Clin Pharmacol 2002, 58:115-118.
29. Lan Q., Rothman N., Chow W.H., et al. No apparent association between NAT1 and NAT2 genotypes and risk of stomach cancer. Cancer Epidemiol Biomarkers Prev 2003, 12:384-386.
30. Suzuki S., Muroishi Y., Nakanishi I., et al. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer. J Gastroenterol 2004, 39:220-230.
31. Hong S.H., Kim J.W., Kim H.G., et al. [Glutathione S-transferases (GSTM1, GSTT1 and GSTP1) and N-acetyltransferase 2 polymorphisms and the risk of gastric cancer]. J Prev Med Public Health 2006, 39:135-140.
32. Al-Moundhri M.S., Al-Kindi M., Al-Nabhani M., et al. NAT2 polymorphism in Omani gastric cancer patients-risk predisposition and clinicopathological associations. World J Gastroenterol 2007, 13:2697-2702.
33. Boccia S., Sayed-Tabatabaei F.A., Persiani R., et al. Polymorphisms in metabolic genes, their combination and interaction with tobacco smoke and alcohol consumption and risk of gastric cancer: a case-control study in an Italian population. BMC Cancer 2007, 7:206.
34. Shen X., Zhang J., Yan Y., et al. Analysis and estimates of the attributable risk for environmental and genetic risk factors in gastric cancer in a Chinese population. J Toxicol Environ Health A 2009, 72:759-766.
35. Zhang Y.W., Eom S.Y., Kim Y.D., et al. Effects of dietary factors and the NAT2 acetylator status on gastric cancer in Koreans. Int J Cancer 2009, 125:139-145.
36. Malik M.A., Upadhyay R., Modi D.R., et al. Association of NAT2 gene polymorphisms with susceptibility to esophageal and gastric cancers in the Kashmir Valley. Arch Med Res 2009, 40:416-423.
37. Hosseini H., Dovranehgard F., Arveysi S., et al. No association between N-acetyltransferase 2 (NAT2) and risk of diffuse type of gastric cancer. Toxicol Lett 2009, 189:S138.
38. Kobayashi M., Otani T., Iwasaki M., et al. Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomach cancer: a hospital-based case-control study in Japan. Gastric Cancer 2009, 12:198-205.
39. Agudo A., Sala N., Pera G., et al. No association between polymorphisms in CYP2E1, GSTM1, NAT1, NAT2 and the risk of gastric adenocarcinoma in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2006, 15:1043-1045.
40. Rouissi K., Ouerhani S., Marrakchi R., et al. Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population. Cancer Genet Cytogenet 2009, 190:101-107.
41. Zienolddiny S., Campa D., Lind H., et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis 2008, 29:1164-1169.
42. Johns L.E., Houlston R.S. N-acetyl transferase-2 and bladder cancer risk: a meta-analysis. Environ Mol Mutagen 2000, 36:221-227.
43. Marcus P.M., Vineis P., Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 2000, 10:115-122.
44. Borlak J., Reamon-Buettner S.M. N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients. BMC Med Genet 2006, 7:58.
45. Raimondi S., Botteri E., Iodice S., et al. Gene-smoking interaction on colorectal adenoma and cancer risk: review and meta-analysis. Mutat Res 2009, 670:6-14.
46. Garcia-Martin E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab 2008, 9:487-497.